• 1
    Ascher B, Coleman S, Alster T, et al. Full scope of effect of facial lipoatrophy: a framework of disease understanding. Dermatol Surg 2006;32:105869.
  • 2
    Carruthers A, Carruthers J. Botulinum toxin type A: history and current cosmetic use in the upper face. Semin Cutan Med Surg 2001;20:7184.
  • 3
    Rzany B, Dill-Müller D, Grablowitz D, et al. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. Dermatol Surg 2007;33 (1 Spec No.):S1825.
  • 4
    Ascher B, Bui P, Halabi A. Fillers in Europe. In: GoldbergD, editor. Fillers in Cosmetic Dermatology. Abingdon, UK: Informa Publications; 2006. p. 12750.
  • 5
    Ascher B, Klap P, Marion MH, Chanteloub F. Botulinum toxin in the treatment of frontoglabellar and periorbital wrinkles. An initial study. Ann Chir Plast Esthet 1995;40:6776.
  • 6
    Feller G, Bayerl C, Jung EG, Rzany B. Treatment of dynamic facial wrinkles with Botulinum Toxin Type A (Dysport®), a pilot study. Akt Dermatol 2000;26:659.
  • 7
    Becker-Wegerich P, Rauch L, Ruzicka T. Botulinum toxin A in the therapy of mimic facial lines. Clin Exp Dermatol 2001;26:61930.
  • 8
    Ascher B, Rossi B. Botulinum toxin and wrinkles: few side effects and effective combining procedures with other treatments. Ann Chir Plast Esthet 2004;49:53752.
  • 9
    Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004;51:22333.
  • 10
    Ascher B, Zakine B, Kestemont P, et al. Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surg J 2005;25:36575.
  • 11
    Keen M, Kopelman JE, Aviv JE, et al. Botulinum toxin A: a novel method to remove periorbital wrinkles. Facial Plast Surg 1994;10:1416.
  • 12
    Ellis DA, Tan AK. Cosmetic upper-facial rejuvenation with botulinum. J Otolaryngol 1997;26:926.
  • 13
    Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 2003;29:713; discussion.
  • 14
    Lowe NJ, Ascher B, Heckmann M, et al. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 2005;31:25762.
  • 15
    Lowe NJ, Lask G, Yamauchi P, Moore D. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. J Am Acad Dermatol 2002;47:83440.
  • 16
    Moore PM, Naumann M. Cosmetic Indications. Handbook of Botulinum Toxin Treatment. 2nd ed. Malden, MA: Blackwell Science; 2002.
  • 17
    Hund T, Ascher B, Rzany B. Reproducibility of two four-point clinical severity scores for lateral canthal lines (crow's feet). Dermatol Surg 2006;32:125660.
  • 18
    Chi George YH. Multiple testings: multiple comparisons and multiple endpoints. Drug Inform J 1998;32:1347S62S.
  • 19
    Rzany B, Ascher B, Fratila A, et al. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006;142:3206.
  • 20
    Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 2007;33 (1 Spec No.):S519.